Prevalence of Smell , Taste and Chemesthesis Disorders among Patients with the Omicron Variant of SARS-CoV-2 in China

Ying Chen [1,†], Yuying Chen [1,†], Xiang Liu [2], Chao Yan [3], Laiquan Zou [1,*]

[1] Chemical Senses and Mental Health Lab, Department of Psychology, School of Public Health, Southern Medical University, Guangzhou, Guangdong, China

[2] Department of Otolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

[3] Key Laboratory of Brain Functional Genomics (MOE&STCSM), Shanghai Changning-ECNU Mental Health Center, School of Psychology and Cognitive Science, East China Normal University, Shanghai, China

[†] These authors contributed equally to this work.

[*]Corresponding Author: Laiquan Zou, Chemical Senses and Mental Health Lab, Department of Psychology, School of Public Health, Southern Medical University, Guangzhou, Guangdong, China; Email: zoulq@smu.edu.cn

Abstract

Many studies have confirmed that chemosensory disorder (including smell, taste and chemesthesis) is one of the symptoms of COVID-19 infection. However, new data indicated that the changes of chemosensory sensation caused by COVID-19 may be different among different populations and COVID-19 variants. At present, there are few studies focusing on the influence of Omicron on qualitative changes and quantitative reductions of chemosensory in China. We conducted a cross-sectional study on COVID-19 Omicron variant patients to investigate the prevalence of chemosensory disorders and their chemosensory function before and during infection by online questionnaire. A total of 1245 patients with COVID-19 completed the study. The prevalence of smell, taste and chemesthesis disorder was 69.2%, 67.7% and 31.4% respectively. Sex, age, smoking and COVID-19-related symptoms such as lack of appetite, dyspnea and fatigue may have association with chemosensory disorders during COVID-19. Self-ratings of chemosensory function revealed that patients experienced a decline in the function of smell, taste and chemesthesis generally. Further studies are needed to combine the data using objective assessment and investigate the factors affecting chemosensory in COVID-19 through longitudinal research.

Introduction

In December 2019, coronavirus disease 2019 (COVID-19) was firstly detected in Wuhan and rapidly spread throughout more than 80 countries (Zhu et al. 2020; Guan et al. 2020). Information from the World Health Organization (WHO) shows that the number of confirmed COVID-19 cases was 756,411,740 by 16 February, 2023 (https://covid19.who.int). Some reports has shown that chemosensory disorders are important symptoms of COVID-19 infection (Al-Rawi et al. 2022; Lee et al. 2022; Parma et al. 2020). Studies from the United States, Europe, Malaysia and Singapore showed that 12%-88% of COVID-19 infected patients have olfactory and taste disorders (Lechien et al. 2020; Menni et al. 2020; Lee et al. 2022; Tham et al. 2021). The study from China reported 5%-25% patients have smell and/or taste disorder(Jia Song et al. 2021; Mao et al. 2020). Omicron variant, which firstly detected in South Africa in November 2021, has become the main epidemic strain in the world by 15 January 2022 (Menni et al. 2022; Hu et al. 2022). Some studies found that Omicron variant cause less smell and taste dysfunction than Non-omicron (Chee et al. 2023; Rodriguez-Sevilla, Güerri-Fernádez, and Bertran Recasens 2022; von Bartheld and Wang 2023). According to a Meta-Analysis, the prevalence of olfactory dysfunction caused by the Omicron variant is 8-17% and 2-17% separately in UK and USA (von Bartheld and Wang 2023).

In China, the prevalence of olfactory dysfunction caused by the Omicron variant is 0-9% (Li et al. 2022; Liang et al. 2022; Yang et al. 2022; Zhang et al. 2022; Shen et al. 2022). However, the sample size is relatively small and the researchers focus on

the characteristics and clinical symptoms with insufficient discussion on chemosensory changes. Chemosensory sensation (including smell, taste and chemesthesis) plays the important role of sensing potential threats , such as toxins, bacteria, and chemical irritants(Green 2012). But most related studies only focus on smell and taste, ignoring chemesthesis (detects burning, cooling or tingling in the mouth)(Green 2012; Parma et al. 2020). Since these three systems are independent sensory systems with distinct peripheral and central neural mechanisms (Speth et al. 2020). It is necessary to explore the influence of COVID-19 on these three senses separately. On the other hand, chemosensory disturbances may result in qualitative changes or quantitative reductions in smell or taste, which related to different mechanisms. Qualitative changes include parosmia (things smell different from usual), phantosmia (hallucination of olfactory senses), smell fluctuation, parageusia (distorted taste sensations) and phantogeusia (hallucination of gustatory senses). Quantitative reductions include anosmia (complete loss of olfaction), hyposmia (partial loss of olfaction), ageusia (loss of all or specific gustatory senses) and hypogeusia (reduced ability to taste things) (Iannilli et al. 2019; Epstein, Smutzer, and Doty 2016). Previous studies have generally explored the changes or the reductions of smell and taste, rarely classified according to the qualitative of the disorders.

There is a pressing need to carry out a cross-sectional study to assess Omicron patients' smell, taste, and chemesthesis disorders in China. The aim of this study was to investigate the prevalence of chemosensory disorders, qualitative and quantitative changes of chemosensory senses during Omicron infection period. A secondary aim

was to identify factors affecting chemosensory disorders, including sex, age, alcohol intake, chronic rhinitis, allergic rhinitis, comorbidity or special condition and COVID-19 related characteristics.

Method

Participants

Participants in an online survey answered questions about their sociodemographic situation, COVID-19 situation and smell, taste, and chemesthesis situation between 20 December 2022 and 20 January 2023. Totally 1311 patients recovered from COVID-19 were invited to participate in the survey (all aged ≥ 18 years). Participants who did not completely answer all the questions or failed to pass the lie test were excluded. The final sample consisted of 1245 participants: 983 women (79.0%) and 262 men (21.0%), with an average age of 25.45 ± 6.57 years old (mean ± sd). As this was a cross-sectional study, a 0.95 power estimate, an effect size of 0.3, and an α of 0.05 were used in the G*Power program to calculate the necessary sample size (Faul et al. 2007). The sample size in our study was far larger than the result proposed by the G*Power program. All participants have read the informed consent form and agreed to use their data for research. This study received ethics approval from the Ethics Committee of Southern Medical University.

Data collection

A self-administered questionnaire was used to survey patients recoveried from

COVID-19 in China. The questionnaire was adapted from an existing online questionnaires developed by the Global Consortium for Chemosensory Research (GCCR)(Parma et al. 2020). The GCCR core questionnaire that implemented in 10 languages as of April 18, 2020 was used or adapted in many other research(Lee et al. 2022; Cecchetto et al. 2021; Albayay et al. 2022). Data collected included the demographic, COVID-19-related characteristics and chemosensory situation before and during infection. In order to further study the sense of smell and taste in detail, the smell situation options include anosmia, hyposmia, parosmia, phantosmia and smell fluctuation, and the taste situation options include ageusia, hypogeusia, parageusia, phantogeusia (Parma et al. 2020; Epstein, Smutzer, and Doty 2016).

Statistics analysis

Associations between categorical variables were tested using Chi-Square test. Self-ratings of smell, taste and chemesthesis before and during COVID-19 diagnosis were tested with Wilcoxon matched pairs signed-rank test. Statistical significance was set at $p < 0.05$ and all reported p values were two tailed. All statistical analyses were performed using IBM SPSS Statistics (SPSS) version 22.

Results

General prevalence

Out of 1245 COVID-19 patients, 69.2% (861/1245) patients reported having smell disorder, 67.7% (843/1245) patients reported having taste disorder, and 31.4%

(391/1245) patients reported having chemesthesis disorder (Table 1). Table 1 also shows the prevalence of specific types of smell and taste disorder. Among the patients experienced anosmia or hyposmia (n = 819), only 12.3% (101/819) of them reported that the anosmia or hyposmia was completely caused by nasal congestion. Besides, 56.9% (708/1245) patients reported loss of both smell and taste, 12.3% (153/1245) reported loss of smell only, and 10.8% (135/1245) reported loss of taste only.

Smell disorder

Table 2 shows that there was statistically significant difference between patients with and without smell disorder for smoking status ($p < 0.05$). According to multiple comparisons, smell disorder was significantly more common among the patients who smoke formerly or currently ($p < 0.05$). No statistically significant difference was found between patients with and without smell disorder for other demographic characteristics such as sex, age groups, alcohol intake, chronic rhinitis, allergic rhinitis and comorbidity or special condition (all $p > 0.05$). Significant differences were also observed between patients with and without smell disorder in the rehabilitation status, COVID-19-related symptoms (lack of appetite, throat dryness and sore, myalgia, stuffy/running nose, dyspnea and fatigue), and COVID-19 vaccination status (all $p < 0.05$). Chi-square analysis reflected that patients with symptoms such as lack of appetite, throat dryness and sore, myalgia, stuffy/running nose, dyspnea and fatigue were prone to have smell disorder. Besides, patients who did not take any COVID-19 vaccination were more possible to have smell disorder (p

< 0.05). The association between specific types of smell disorder (anosmia, hyposmia, paraosmia, phantosmia and olfactory fluctuation) and demographic/COVID-19-related characteristics was shown in supplemental material (Table S1-S5).

Only 4.8% (60/1245) patients reported paraosmia and 7.9% (98/1245) patients reported phantosmia. The pleasantness rating score of the distorted smell caused by paraosmia was 25.72 ± 24.81 (Mean ± SD, 100-point scale), and the score of the phantom smell was 26.74 ± 25.98 (Mean ± SD). Parosmic individuals mostly reported the smell of food (e.g. meat, rice, soup) or other daily necessities (e.g. toothpaste, shampoo, liquid detergent) that became roasted burnt, or spoiled (e.g. “The smell of the chicken soup turned to burning”). In phantosmic individuals, most frequently reported phantom smell was smoky, burnt and rotten.

Patients rated their smell function before and during COVID-19 on a 100-point scale. Compared to the score before COVID-19 (88.53 ± 13.24, Mean ± SD), the score during COVID-19 (52.38 ± 32.83, Mean ± SD) was significantly lower ($t = 38.386$, $p < 0.001$, Figure 1).

Taste disorder

There was no statistically significant difference between patients with and without taste disorder for demographic characteristics such as sex, age groups, smoking/alcohol intake (all $p > 0.05$, Table 3). Patients with COVID-19-related symptoms such as lack of appetite, throat dryness and sore, myalgia, headache,

diarrhea, cough/expectoration, stuffy/running nose, dyspnea and fatigue had significant chance of experiencing taste disorder (all $p < 0.05$). The association between specific types of taste disorder (ageusia, hypogeusia, parageusia, phantogeusia) and demographic/COVID-19-related characteristics was shown in supplemental material (Table S6-S9). Additionally, in patients with total loss or decrease of specific taste (n = 597), 36.9% of them (220/597) reported a total loss or decrease in the taste of sour, 45.9% (274/597) for sweet, 20.1% (120/597) for bitter, 51.4% (307/597) for salty, and 71.9% (429/597) for umami.

Parageusia was described in 22.7% (282/1245) patients, and phantogeusia was identified in 26.7% (333/1245) patients. The pleasantness rating score of the distorted gustatory sense caused by parageusia was 19.80 ± 21.33 (Mean ± SD, 100-point scale), and the score of the gustatory hallucination was 24.97 ± 34.38. Most patients with parageusia described that the flavor of food such as orange, meat or candy became bitter (e.g. “The rice has turned bitter”). Patients with phantogeusia most frequently reported the constant flavor of bitter without anything in mouth.

Similar to smell, patients rated their taste function before and during COVID-19. The score during COVID-19 (58.78 ± 29.74, Mean ± SD) was significantly lower than the score before COVID-19 (90.13 ± 11.60, Mean ± SD) ($t = 37.173$, $p < 0.001$).

Chemesthesis disorder

No significant difference was found between patients with and without chemesthesis disorder for demographic characteristics including sex, age groups, smoking and

alcohol intake, chronic rhinitis, allergic rhinitis and any comorbidity or special condition (all $p > 0.05$, Table 4). For COVID-19-related symptoms (lack of appetite, dyspnea and fatigue) significant difference was detected between patients with and without chemesthesis disorder (all $p < 0.05$).

Patients also rated their chemesthesis function before and during COVID-19. The score during COVID-19 (71.82 ± 26.48, Mean ± SD) was also significantly lower than the score before COVID-19 (88.50 ± 15.83, Mean ± SD) ($t = 24.700$, $p < 0.001$).

Discussion

In the current study, we found that the prevalence of smell, taste and chemesthesis disorder in 1245 patients with COVID-19 during the period of Omicron variant dominance was about 69.2%, 67.7% and 31.4% respectively. Previous studies reported the prevalence of olfactory dysfunction ranging from 3.2% to 98.3% and taste dysfunction ranging from 5.6% to 62.7% (Jian Song et al. 2023; Agyeman et al. 2020). The prevalence of smell, taste and chemesthesis disorder in previous research was various among different population, assessment methods and virus strains (Jian Song et al. 2023). A meta-analysis based on data from 24 studies including over 8400 participants from 13 countries found the pooled prevalence of patients with smell and taste dysfunction was 41.0% and 38.2% (Agyeman et al. 2020). Another meta-analysis involving 18 studies showed that the prevalence of alteration of the sense of smell or taste was 47% (Borsetto et al. 2020). Importantly, recent studies mostly focused on quantitative changes of smell and taste, the qualitative changes of

smell and taste were not included (Luers et al. 2020; Mercante et al. 2020; Pellegrino et al. 2021; Agyeman et al. 2020). However, the smell disorder in our study includes five types (anosmia, hyposmia, paraosmia, phantosmia and olfactory fluctuation), and the taste disorder includes four types (ageusia, hypogeusia, parageusia, phantogeusia). The prevalence of anosmia in our study was 23.3%, hyposmia was 42.5%, ageusia was 19.0% and hypogeusia was 40.1%. Studies have also found that the prevalence of smell and taste disorder has decreased in the period of Omicron variant dominance but it still more than 30%, which was similar to our study (Boscolo□Rizzo et al. 2022; Jian Song et al. 2023).

Some studies showed that males are more prone to loss of smell and taste senses than females (Al-Ani and Acharya 2022). Our study demonstrated that females are more prone to completely loss of olfaction, which is similar to Lechien et al (Lechien et al. 2020; Tham et al. 2021). In terms of taste loss, we did not detect significant differences between sexes, which is similar to Al-Rawi et al (Al-Rawi et al. 2022; Moein et al. 2020). Al-Rawi et al found a more significant smell and taste declination in individuals in their late 30s (Al-Rawi et al. 2022). We concluded the similar result that 30-39 years old patients are more prone to anosmia and ageusia. Previous research showed that the smokers are more vulnerable to anosmia and ageusia (Al-Ani and Acharya 2022). However, no significant differences were detected between smokers and non-smokers in terms of anosmia and ageusia in our study. Interestingly, we found that smoking has adverse effects on general smell disorders.

We also found that some COVID-19 related symptoms affect the proportion of

chemosensory disorders, such as lack of appetite, dyspnea and fatigue. These factors associated with chemosensory disorders have been reported in previous research (Menni et al. 2020; Tham et al. 2021). But whether they are risk factors for chemosensory disorders still needs further study.

In the current study, we reported the prevalence, quality and quantity changes of chemosensory of patients infected with Omicron variant in China. Patients often confuse chemesthesis with smell and taste when self-reporting, thus our survey expanded the part of chemesthesis, which can better distinguish the influence of COVID-19 infection on smell, taste and chemesthesis. We have also made a detailed distinction in the quality and quantity changes of smell and taste. We found these changes differed in COVID-19 infected population, which may provide reference for the follow-up research on the mechanism of COVID-19 influence on smell and taste. Moreover, we expanded the Chinese version of GCCR core questionnaire to provide reference for future domestic research.

Our study also had several limitations. First, the participants in our study were mostly from the southern areas of China. Second, the collection of the data in our study was based on self-report, which may lead to bias in the confirm of chemosensory disorders. The combination of objective assessment of chemosensory disorders is needed in future study. Third, our study was cross-sectional, longitudinal studies are needed to determine the direction of associations among variables in our study.

Conclusion

The current study found the prevalence of smell, taste and chemesthesis disorder in 1245 patients with COVID-19 during the period of Omicron variant dominance was about 69.2%, 67.7% and 31.4%. Patients experienced a decline in the function of smell, taste and chemesthesis generally. Sex, age, smoking and COVID-19-related symptoms such as lack of appetite, dyspnea and fatigue may have association with chemosensory disorders during COVID-19. The present study contributes to existing knowledge of chemosensory disorders in COVID-19 by providing Chinese data during Omicron variant.

References

Agyeman, Akosua Adom, Ken L. Chin, Cornelia B. Landersdorfer, Danny Liew, and Richard Ofori-Asenso. 2020. "Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-Analysis." *Mayo Clinic Proceedings* 95 (8): 1621–31. https://doi.org/10.1016/j.mayocp.2020.05.030.

Al-Ani, Raid M., and Debashis Acharya. 2022. "Prevalence of Anosmia and Ageusia in Patients with COVID-19 at a Primary Health Center, Doha, Qatar." *Indian Journal of Otolaryngology and Head & Neck Surgery* 74 (S2): 2703–9. https://doi.org/10.1007/s12070-020-02064-9.

Albayay, Javier, Lara Fontana, Valentina Parma, and Massimiliano Zampini. 2022. "Chemosensory Dysfunction in Long-Term COVID-19 Assessed by Self-Reported and Direct Psychophysical Methods." *Life* 12 (10): 1487. https://doi.org/10.3390/life12101487.

Al-Rawi, Natheer H., Ayat R. Sammouda, Eman A. AlRahin, Fatma A. Al Ali, Ghadeer S. Al Arayedh, Hamideh A. Daryanavard, Musab H. Saeed, and Ahmed S. Al Nuaimi. 2022. "Prevalence of Anosmia or Ageusia in Patients With COVID-19 Among United Arab Emirates Population." *International Dental Journal* 72 (2): 249–56. https://doi.org/10.1016/j.identj.2021.05.006.

Bartheld, Christopher S. von, and Lingchen Wang. 2023. "Prevalence of Olfactory Dysfunction with the Omicron Variant of SARS-CoV-2: A Systematic Review and Meta-Analysis." *Cells* 12 (3): 430. https://doi.org/10.3390/cells12030430.

Borsetto, D, C Hopkins, V Philips, R Obholzer, G Tirelli, J Polesel, and P Boscolo-Rizzo. 2020. "Self-Reported Alteration of Sense of Smell or Taste in Patients with COVID-19: A Systematic Review and Meta-Analysis on 3563 Patients." *Rhinology* 58 (5): 430–36. https://doi.org/10.4193/rhin20.185.

Boscolo□Rizzo, Paolo, Giancarlo Tirelli, Pierluigi Meloni, Claire Hopkins, Giordano Madeddu, Andrea De Vito, Nicoletta Gardenal, et al. 2022. "Coronavirus Disease 2019 (COVID□19)–Related Smell and Taste Impairment with Widespread Diffusion of Severe Acute Respiratory Syndrome–Coronavirus□2 (SARS□CoV□2) Omicron Variant." *International Forum of Allergy & Rhinology* 12 (10): 1273–81. https://doi.org/10.1002/alr.22995.

Cecchetto, Cinzia, Antonella Di Pizio, Federica Genovese, Orietta Calcinoni, Alberto Macchi, Andreas Dunkel, Kathrin Ohla, et al. 2021. "Assessing the Extent and Timing of Chemosensory Impairments during COVID-19 Pandemic." *Scientific Reports* 11 (1): 17504. https://doi.org/10.1038/s41598-021-96987-0.

Chee, Jeremy, Beverlyn Chern, Woei Shyang Loh, Joaquim Mullol, and De Yun Wang. 2023. "Pathophysiology of SARS-CoV-2 Infection of Nasal Respiratory and Olfactory Epithelia and Its Clinical Impact." *Current Allergy and Asthma Reports* 23 (2): 121–31. https://doi.org/10.1007/s11882-022-01059-6.

Epstein, Joel B., Gregory Smutzer, and Richard L. Doty. 2016. "Understanding the Impact of Taste Changes in Oncology Care." *Supportive Care in Cancer* 24 (4): 1917–31. https://doi.org/10.1007/s00520-016-3083-8.

Faul, Franz, Edgar Erdfelder, Albert-Georg Lang, and Axel Buchner. 2007. "G*Power 3: A Flexible Statistical Power Analysis Program for the Social, Behavioral, and Biomedical

Sciences.” *Behavior Research Methods* 39 (2): 175–91. https://doi.org/10.3758/BF03193146.

Green, B. G. 2012. “Chemesthesis and the Chemical Senses as Components of a ‘Chemofensor Complex.’” *Chemical Senses* 37 (3): 201–6. https://doi.org/10.1093/chemse/bjr119.

Guan, Wei-jie, Zheng-yi Ni, Yu Hu, Wen-hua Liang, Chun-quan Ou, Jian-xing He, Lei Liu, et al. 2020. “Clinical Characteristics of Coronavirus Disease 2019 in China.” *New England Journal of Medicine* 382 (18): 1708–20. https://doi.org/10.1056/NEJMoa2002032.

Hu, Jie, Pai Peng, Xiaoxia Cao, Kang Wu, Juan Chen, Kai Wang, Ni Tang, and Ai-long Huang. 2022. “Increased Immune Escape of the New SARS-CoV-2 Variant of Concern Omicron.” *Cellular & Molecular Immunology* 19 (2): 293–95. https://doi.org/10.1038/s41423-021-00836-z.

Iannilli, Emilia, Donald A. Leopold, David E. Hornung, and Thomas Hummel. 2019. “Advances in Understanding Parosmia: An FMRI Study.” *ORL* 81 (4): 185–92. https://doi.org/10.1159/000500558.

Lechien, Jerome R., Carlos M. Chiesa-Estomba, Daniele R. De Siati, Mihaela Horoi, Serge D. Le Bon, Alexandra Rodriguez, Didier Dequanter, et al. 2020. “Olfactory and Gustatory Dysfunctions as a Clinical Presentation of Mild-to-Moderate Forms of the Coronavirus Disease (COVID-19): A Multicenter European Study.” *European Archives of Oto-Rhino-Laryngology* 277 (8): 2251–61. https://doi.org/10.1007/s00405-020-05965-1.

Lee, Shen-Han, Zhi Xiang Yeoh, Ida Sadja’ah Sachlin, Norzi Gazali, Shahrul Aiman Soelar, Chee Yoong Foo, Lee Lee Low, et al. 2022. “Self-Reported Symptom Study of COVID-19 Chemosensory Dysfunction in Malaysia.” *Scientific Reports* 12 (1): 2111. https://doi.org/10.1038/s41598-022-06029-6.

Li, Qinggang, Xiaorui Liu, Lei Li, Xiaobo Hu, Guangying Cui, Ranran Sun, Donghua Zhang, et al. 2022. “Comparison of Clinical Characteristics between SARS-CoV-2 Omicron Variant and Delta Variant Infections in China.” *Frontiers in Medicine* 9 (October): 944909. https://doi.org/10.3389/fmed.2022.944909.

Liang, Yibo, Xiang Mao, Manbao Kuang, Jingtai Zhi, Ziyue Zhang, Mingyu Bo, Guimin Zhang, Peng Lin, Wei Wang, and Zhongyang Shen. 2022. “Interleukin-6 Affects the Severity of Olfactory Disorder: A Cross-Sectional Survey of 148 Patients Who Recovered from Omicron Infection Using the Sniffin’ Sticks Test in Tianjin, China.” *International Journal of Infectious Diseases* 123 (October): 17–24. https://doi.org/10.1016/j.ijid.2022.07.074.

Luers, Jan C., Alexander C. Rokohl, Niklas Loreck, Philomena A. Wawer Matos, Max Augustin, Felix Dewald, Florian Klein, Clara Lehmann, and Ludwig M. Heindl. 2020. “Olfactory and Gustatory Dysfunction in Coronavirus Disease 2019 (COVID-19).” *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America* 71 (16): 2262–64. https://doi.org/10.1093/cid/ciaa525.

Mao, Ling, Huijuan Jin, Mengdie Wang, Yu Hu, Shengcai Chen, Quanwei He, Jiang Chang, et al. 2020. “Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China.” *JAMA Neurology* 77 (6): 683. https://doi.org/10.1001/jamaneurol.2020.1127.

Menni, Cristina, Ana M. Valdes, Maxim B. Freidin, Carole H. Sudre, Long H. Nguyen, David A. Drew, Sajaysurya Ganesh, et al. 2020. “Real-Time Tracking of Self-Reported Symptoms to Predict Potential COVID-19.” *Nature Medicine* 26 (7): 1037–40.

https://doi.org/10.1038/s41591-020-0916-2.

Menni, Cristina, Ana M Valdes, Lorenzo Polidori, Michela Antonelli, Satya Penamakuri, Ana Nogal, Panayiotis Louca, et al. 2022. “Symptom Prevalence, Duration, and Risk of Hospital Admission in Individuals Infected with SARS-CoV-2 during Periods of Omicron and Delta Variant Dominance: A Prospective Observational Study from the ZOE COVID Study.” *The Lancet* 399 (10335): 1618–24. https://doi.org/10.1016/S0140-6736(22)00327-0.

Mercante, Giuseppe, Fabio Ferreli, Armando De Virgilio, Francesca Gaino, Matteo Di Bari, Giovanni Colombo, Elena Russo, et al. 2020. “Prevalence of Taste and Smell Dysfunction in Coronavirus Disease 2019.” *JAMA Otolaryngology-- Head & Neck Surgery* 146 (8): 1–6. https://doi.org/10.1001/jamaoto.2020.1155.

Moein, Shima T., Seyed MohammadReza Hashemian, Babak Mansourafshar, Ali Khorram□Tousi, Payam Tabarsi, and Richard L. Doty. 2020. “Smell Dysfunction: A Biomarker for COVID□19.” *International Forum of Allergy & Rhinology* 10 (8): 944–50. https://doi.org/10.1002/alr.22587.

Parma, Valentina, Kathrin Ohla, Maria G Veldhuizen, Masha Y Niv, Christine E Kelly, Alyssa J Bakke, Keiland W Cooper, et al. 2020. “More Than Smell—COVID-19 Is Associated With Severe Impairment of Smell, Taste, and Chemesthesis.” *Chemical Senses* 45 (7): 609–22. https://doi.org/10.1093/chemse/bjaa041.

Pellegrino, Robert, Joel D Mainland, Christine E Kelly, Jane K Parker, and Thomas Hummel. 2021. “Prevalence and Correlates of Parosmia and Phantosmia among Smell Disorders.” *Chemical Senses* 46 (October): bjab046. https://doi.org/10.1093/chemse/bjab046.

Rodriguez-Sevilla, Juan Jose, Roberto Güerri-Fernádez, and Bernat Bertran Recasens. 2022. “Is There Less Alteration of Smell Sensation in Patients With Omicron SARS-CoV-2 Variant Infection?” *Frontiers in Medicine* 9 (April): 852998. https://doi.org/10.3389/fmed.2022.852998.

Shen, Jun, Li Wu, Ping Wang, Xiaolei Shen, Yuhan Jiang, Jianren Liu, and Wei Chen. 2022. “Clinical Characteristics and Short-Term Recovery of Hyposmia in Hospitalized Non-Severe COVID-19 Patients with Omicron Variant in Shanghai, China.” *Frontiers in Medicine* 9 (November): 1038938. https://doi.org/10.3389/fmed.2022.1038938.

Song, Jia, Yi-ke Deng, Hai Wang, Zhi-chao Wang, Bo Liao, Jin Ma, Chao He, et al. 2021. “Self-Reported Taste and Smell Disorders in Patients with COVID-19: Distinct Features in China.”

Song, Jian, Qi Jing, Enzhao Zhu, Qidong Liu, Miaomiao Fei, Hui Zhang, Guanghui An, et al. 2023. “Alterations in Smell or Taste in Individuals Infected with SARS-CoV-2 during Periods of Omicron Variant Dominance.” *International Journal of Infectious Diseases* 128 (March): 278–84. https://doi.org/10.1016/j.ijid.2023.01.017.

Speth, Marlene M., Thirza Singer-Cornelius, Michael Oberle, Isabelle Gengler, Steffi J. Brockmeier, and Ahmad R. Sedaghat. 2020. “Olfactory Dysfunction and Sinonasal Symptomatology in COVID-19: Prevalence, Severity, Timing, and Associated Characteristics.” *Otolaryngology–Head and Neck Surgery* 163 (1): 114–20. https://doi.org/10.1177/0194599820929185.

Tham, Alex C., Tun-Linn Thein, Chrisanda S. Lee, Glorijoy S. E. Tan, Charmaine M. Manauis, J. K. Siow, Y. S. Leo, and M. Y. Lim. 2021. “Olfactory Taste Disorder as a Presenting

Symptom of COVID-19: A Large Single-Center Singapore Study." *European Archives of Oto-Rhino-Laryngology* 278 (6): 1853–62. https://doi.org/10.1007/s00405-020-06455-0.

Yang, Wei, Songliu Yang, Lei Wang, Yuxin Zhou, Yu Xin, Hongxu Li, Wenjing Mu, et al. 2022. "Clinical Characteristics of 310 SARS-CoV-2 Omicron Variant Patients and Comparison with Delta and Beta Variant Patients in China." *Virologica Sinica* 37 (5): 704–15. https://doi.org/10.1016/j.virs.2022.07.014.

Zhang, Huatang, Wenhuang Chen, Xiaoyi Ye, Yongjun Zhou, Yijuan Zheng, Zhangyan Weng, Jianfeng Xie, et al. 2022. "Clinical Characteristics of Patients Infected with Novel Coronavirus Wild Strain, Delta Variant Strain and Omicron Variant Strain in Quanzhou: A Real□world Study." *Experimental and Therapeutic Medicine* 25 (1): 62. https://doi.org/10.3892/etm.2022.11761.

Zhu, Na, Dingyu Zhang, Wenling Wang, Xingwang Li, Bo Yang, Jingdong Song, Xiang Zhao, et al. 2020. "A Novel Coronavirus from Patients with Pneumonia in China, 2019." *New England Journal of Medicine* 382 (8): 727–33. https://doi.org/10.1056/NEJMoa2001017.

Table 1 The prevalence of smell, taste and chemesthesis disorders among COVID-19 patients

Variables	n	prevalence in total (N=1245)	prevalence in people with smell/taste/Chemethesis disorder
Smell disorder*	861	69.2%	\
Anosmia	290	23.3%	33.7%
Hyposmia	529	42.5%	61.4%
Parosmia	60	4.8%	7.0%
Phantosmia	98	7.9%	11.4%
Smell fluctuation	438	35.2%	50.9%
Taste disorder*	843	67.7%	\
Ageusia	236	19.0%	28.0%
Hypogeusia	499	40.1%	59.2%
Parageusia	282	22.7%	33.5%
Phantogeusia	333	26.7%	39.5%
Chemesthesis disorder	391	31.4%	\
Complete loss	35	2.8%	9.0%
Partial loss	356	28.6%	91.0%

*Multiple responses

Table 2 Association between smell disorder and demographic/COVID-19-related characteristics among patients

Variables	Smell disorder (%)		Total (%)	p value
	Yes (n = 861)	No (n = 384)	N = 1245	
Sex				
Male	170 (19.7)	92 (24.0)	262 (21.0)	0.092
Female	691 (80.3)	292 (76.0)	983 (79.0)	
Age, yr				
18-29	702 (81.5)	327 (85.2)	1029 (82.7)	
30-39	116 (13.5)	38 (9.9)	154 (12.4)	0.204
40-49	30 (3.5)	16 (4.2)	46 (3.7)	
≥ 50	13 (1.5)	3 (0.8)	16 (1.3)	
Smoking				
Current	32 (3.7)	5 (1.3)	37 (3.0)	0.012
Former	38 (4.4)	9 (2.3)	47 (3.8)	
Never	791 (91.9)	370 (96.4)	1161 (93.3)	
Alcohol				
Yes	441 (51.2)	184 (47.9)	625 (50.2)	0.282
No	420 (48.8)	200 (52.1)	620 (49.8)	
Chronic rhinitis				
Yes	137 (15.9)	48 (12.5)	185 (14.9)	0.118
No	724 (84.1)	336 (87.5)	1060 (85.1)	
Allergic rhinitis				
Yes	208 (24.2)	91 (23.7)	299 (24.0)	0.861
No	653 (75.8)	293 (76.3)	946 (76.0)	
Any comorbidity or special condition[#]				
Yes	106 (12.3)	42 (10.9)	148 (11.9)	0.489
No	755 (87.7)	342 (89.1)	1097 (88.1)	
Method of diagnosis				
PCR test	134 (15.6)	67 (17.4)	201 (16.1)	
Antigen test	459 (53.3)	200 (52.1)	659 (52.9)	0.706
Symptoms	268 (31.1)	117 (30.5)	385 (30.9)	
Rehabilitation status				
Complete	283 (32.9)	167 (43.5)	450 (36.1)	< 0.001
Partial	578 (67.1)	217 (56.5)	795 (63.9)	
Symptoms[*]				
Fever	818 (95.0)	358 (93.2)	1176 (94.5)	0.206
Lack of appetite	547 (63.5)	168 (43.8)	715 (57.4)	< 0.001
Throat dryness and sore	692 (80.4)	284 (74.0)	976 (78.4)	0.011
Myalgia	604 (70.2)	240 (62.5)	844 (67.8)	0.008
Headache	598 (69.5)	256 (66.7)	854 (68.6)	0.328
Diarrhea	191 (22.2)	71 (18.5)	262 (21.0)	0.140
Cough/expectoration	747 (86.8)	321 (83.6)	1068 (85.8)	0.140
Stuffy/running nose	704 (81.8)	281 (73.2)	985 (79.1)	0.001

Dyspnea	158 (18.4)	43 (11.2)	201 (16.1)	0.002
Fatigue	602 (69.9)	232 (60.4)	834 (67.0)	0.001
COVID-19 vaccination				
Yes (n = 1208)	828 (96.2)	380 (99.0)	1208 (97.0)	0.007
No (n = 37)	33 (3.8)	4 (1.0)	37 (3.0)	

[#] Comorbidity or special condition includes hypertension, diabetes, cardiovascular disease, cerebrovascular disease, neoplastic disease, immune deficiency, chronic kidney disease, thyroid disease, rheumatoid arthritis, spinal joint disease, bronchial asthma, mental illness, and the third pregnancy and perinatal period

[*] Multiple response

Table 3 Association between taste disorder and demographic/COVID-19-related characteristics among patients

Variables	Taste disorder (%)		Total (%)	p value
	Yes (n = 843)	No (n = 402)	Yes (n = 1245)	
Sex				
Male	167 (19.8)	95 (23.6)	262 (21.0)	0.122
Female	676 (80.2)	307 (76.4)	983 (79.0)	
Age, yr				
18-29	687 (81.5)	342 (85.1)	1029 (82.7)	
30-39	113 (13.4)	41 (10.2)	154 (12.4)	0.430
40-49	32 (3.8)	14 (3.5)	46 (3.7)	
≥ 50	11 (1.3)	5 (1.2)	16 (1.3)	
Smoking				
Current	27 (3.2)	10 (2.5)	37 (3.0)	0.194
Former	37 (4.4)	10 (2.5)	47 (3.8)	
Never	779 (92.4)	382 (95.0)	1161 (93.3)	
Alcohol				
Yes	430 (51.0)	195 (48.5)	625 (50.2)	0.409
No	413 (49.0)	207 (51.5)	620 (49.8)	
Chronic rhinitis				
Yes	129 (15.3)	56 (13.9)	185 (14.9)	0.524
No	714 (84.7)	346 (86.1)	1060 (85.1)	
Allergic rhinitis				
Yes	206 (24.4)	93 (23.1)	299 (24.0)	0.615
No	637 (75.6)	309 (76.9)	946 (76.0)	
Any comorbidity or special condition#				
Yes	109 (12.9)	39 (9.7)	148 (11.9)	0.100
No	734 (87.1)	363 (90.3)	1097 (88.1)	
Method of diagnosis				
PCR test	135 (16.0)	66 (16.4)	201 (16.1)	
Antigen test	438 (52.0)	221 (55.0)	659 (52.9)	0.466
Symptoms	270 (32.0)	115 (28.6)	385 (30.9)	
Rehabilitation status				
Complete	292 (34.6)	158 (39.3)	450 (36.1)	0.109
Partial	551 (65.4)	244 (60.7)	795 (63.9)	
Symptoms				
Fever	800 (94.9)	376 (93.5)	1176 (94.5)	0.324
Lack of appetite	554 (65.7)	161 (40.0)	715 (57.4)	< 0.001
Throat dryness and sore	677 (80.3)	299 (74.4)	976 (78.4)	0.017
Myalgia	591 (70.1)	253 (62.9)	844 (67.8)	0.011
Headache	599 (71.1)	255 (63.4)	854 (68.6)	0.007
Diarrhea	196 (23.3)	66 (16.4)	262 (21.0)	0.006
Cough/expectoration	739 (87.7)	329 (81.8)	1068 (85.8)	0.006
Stuffy/running nose	681 (80.8)	304 (75.6)	985 (79.1)	0.036

Dyspnea	158 (18.7)	43 (10.7)	201 (16.1)	< 0.001
Fatigue	598 (70.9)	236 (58.7)	834 (67.0)	< 0.001
COVID-19 vaccination				
Yes	814 (96.6)	394 (98.0)	1208 (97.0)	0.159
No	29 (3.4)	8 (2.0)	37 (3.0)	

[#] Comorbidity or special condition includes hypertension, diabetes, cardiovascular disease, cerebrovascular disease, neoplastic disease, immune deficiency, chronic kidney disease, thyroid disease, rheumatoid arthritis, spinal joint disease, bronchial asthma, mental illness, and the third pregnancy and perinatal period

[*] Multiple response

Table 4 Association between chemesthesis disorder and demographic characteristics among patients

Variables	Chemesthesis disorder (%)		Total (%)	p value
	Yes (n = 391)	No (n = 854)	Yes (n = 1245)	
Sex				
Male	70 (17.9)	192 (22.5)	262 (21.0)	0.066
Female	321 (82.1)	662 (77.5)	983 (79.0)	
Age, yr				
18-29	310 (79.3)	719 (84.2)	1029 (82.7)	
30-39	60 (15.3)	94 (11.0)	154 (12.4)	0.160
40-49	15 (3.8)	31 (3.6)	46 (3.7)	
≥ 50	6 (1.5)	10 (1.2)	16 (1.3)	
Smoking				
Current	12 (3.1)	25 (2.9)	37 (3.0)	0.914
Former	16 (4.1)	31 (3.6)	47 (3.8)	
Never	363 (92.8)	798 (93.4)	1161 (93.3)	
Alcohol				
Yes	203 (51.9)	422 (49.4)	625 (50.2)	0.412
No	188 (48.1)	432 (50.6)	620 (49.8)	
Chronic rhinitis				
Yes	62 (15.9)	123 (14.4)	185 (14.9)	0.503
No	329 (84.1)	731 (85.6)	1060 (85.1)	
Allergic rhinitis				
Yes	86 (22.0)	213 (24.9)	299 (24.0)	0.259
No	305 (78.0)	641 (75.1)	946 (76.0)	
Any comorbidity or special condition[#]				
Yes	49 (12.5)	99 (11.6)	148 (11.9)	0.635
No	342 (87.5)	755 (88.4)	1097 (88.1)	
Method of diagnosis				
PCR test	60 (15.3)	141 (16.5)	201 (16.1)	0.693
Antigen test	204 (52.2)	455 (53.3)	659 (52.9)	
Symptoms	127 (32.5)	258 (30.2)	385 (30.9)	
Rehabilitation status				
Complete	126 (32.2)	324 (37.9)	450 (36.1)	0.051
Partial	265 (67.8)	530 (62.1)	795 (63.9)	
Symptoms[*]				
Fever	369 (94.4)	807 (94.5)	1176 (94.5)	0.930
Lack of appetite	261 (66.8)	454 (53.2)	715 (57.4)	< 0.001
Throat dryness and sore	312 (79.8)	664 (77.8)	976 (78.4)	0.416
Myalgia	270 (69.1)	574 (67.2)	844 (67.8)	0.519
Headache	266 (68.0)	588 (68.9)	854 (68.6)	0.772
Diarrhea	84 (21.5)	178 (20.8)	262 (21.0)	0.797
Cough/expectoration	341 (87.2)	727 (85.1)	1068 (85.8)	0.329
Stuffy/running nose	309 (79.0)	676 (79.2)	985 (79.1)	0.959

Dyspnea	87 (22.3)	114 (13.3)	201 (16.1)	< 0.001
Fatigue	284 (72.6)	550 (64.4)	834 (67.0)	0.004
COVID-19 vaccination				
Yes	374 (95.7)	834 (97.7)	1208 (97.0)	0.053
No	17 (4.3)	20 (2.3)	37 (3.0)	

[#] Comorbidity or special condition includes hypertension, diabetes, cardiovascular disease, cerebrovascular disease, neoplastic disease, immune deficiency, chronic kidney disease, thyroid disease, rheumatoid arthritis, spinal joint disease, bronchial asthma, mental illness, and the third pregnancy and perinatal period

[*] Multiple response



Figure 1 The results of the self-ratings of smell, taste and chemesthesis function

*** $p < 0.001$